Männistö P T, Lang A, Rauhala P, Vasar E
University of Helsinki, Department of Pharmacology and Toxicology, Finland.
Eur J Pharmacol. 1995 Feb 14;274(1-3):229-33. doi: 10.1016/0014-2999(94)00776-4.
The administration of catechol-O-methyltransferase inhibitors alone changed neither the behavior of the rats in two animal models of depression, the forced swimming test (entacapone and tolcapone) or in the learned helplessness paradigm (tolcapone), nor the locomotor activity. L-Dihydroxyphenylalanine (L-DOPA) and carbidopa treatment as such decreased motility but did not improve the behavior in the antidepressant tests. Co-administration of catechol-O-methyltransferase inhibitors and L-DOPA/carbidopa increased the performance of rats in both tests without increasing locomotor activity. Catechol-O-methyltransferase inhibitors could be beneficial as adjunct drugs of L-DOPA not only in Parkinson's disease but also in the coincident depressive illness.
单独给予儿茶酚-O-甲基转移酶抑制剂,在两种抑郁症动物模型(强迫游泳试验,恩他卡朋和托卡朋;习得性无助模型,托卡朋)中均未改变大鼠行为,也未改变其运动活性。左旋多巴(L-DOPA)和卡比多巴治疗本身会降低运动能力,但在抗抑郁试验中并未改善行为。儿茶酚-O-甲基转移酶抑制剂与L-DOPA/卡比多巴联合给药,在两种试验中均提高了大鼠的表现,且未增加运动活性。儿茶酚-O-甲基转移酶抑制剂作为L-DOPA的辅助药物,不仅在帕金森病中,而且在并发的抑郁症中可能有益。